Immuno-oncology

Five things for pharma marketers to know: Thursday, July 6, 2017

Five things for pharma marketers to know: Thursday, July 6, 2017

By

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Back at Dendreon, Caggiano takes on Provenge's comeback

Back at Dendreon, Caggiano takes on Provenge's comeback

By

Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.

Five things for pharma marketers to know: Tuesday, May 2, 2017

Five things for pharma marketers to know: Tuesday, May 2, 2017

By

Sales of Merck's Keytruda double in the first quarter; the FDA approves AstraZeneca's immunotherapy; Lilly's insulin is under investigation in two states

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

By

Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.

Sales of Keytruda miss analysts' mark

Sales of Keytruda miss analysts' mark

By

Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.

Merck's Keytruda combo could edge out the competition

Merck's Keytruda combo could edge out the competition

By

Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.

Five things for pharma marketers to know: Wednesday, January 11, 2017

Five things for pharma marketers to know: Wednesday, January 11, 2017

By

The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts

Merck kicks off lung-cancer campaign

Merck kicks off lung-cancer campaign

By

On the heels of Keytruda's approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about biomarkers.

Merck's Keytruda wins approval in first-line lung cancer

Merck's Keytruda wins approval in first-line lung cancer

By

Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.

Five things for pharma marketers to know: Friday, October 14, 2016

Five things for pharma marketers to know: Friday, October 14, 2016

By

Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

By

One analyst envisions how a first-line approval could set up Keytruda for success in other settings.

DTC ads for Opdivo face further backlash

DTC ads for Opdivo face further backlash

By

Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.

Five things for pharma marketers to know: Tuesday, July 26, 2016

Five things for pharma marketers to know: Tuesday, July 26, 2016

By

Sales of Gilead's HCV drugs fall; the DNC policy platform criticized price gouging; Janssen partners with Bristol-Myers Squibb on Opdivo combo drug

Five things for pharma marketers to know: Friday, June 10, 2016

By

FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

By

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

Five things for pharma marketers to know: Friday, April 15, 2016

Five things for pharma marketers to know: Friday, April 15, 2016

By

Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs

Drugmakers partner in immuno-oncology, to better capture market share

Drugmakers partner in immuno-oncology, to better capture market share

By

Manufacturers team up to study drug combinations, a strategy expected to advance the category.

Five things for pharma marketers to know: Friday, February 19, 2016

Five things for pharma marketers to know: Friday, February 19, 2016

By

Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise

Five things for pharma marketers to know: Monday, January 11, 2016

Five things for pharma marketers to know: Monday, January 11, 2016

By

Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

By

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

Five things for pharma marketers to know: Tuesday, November 24, 2015

Five things for pharma marketers to know: Tuesday, November 24, 2015

By

Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease

Five things for pharma marketers to know: Thursday, October 1, 2015

Five things for pharma marketers to know: Thursday, October 1, 2015

By

The FDA approves Opdivo/Yervoy combination to treat melanoma; BioMarin acquires global rights to Kuvan; Allergan's Juvederm receives marketing approval for lip augmentation

Bristol-Myers Squibb promotes employees

Bristol-Myers Squibb promotes employees

By

The drugmaker launched its first YouTube channel as it kicked off the campaign.

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

By

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

By

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe